1. Home
  2. News Archive

More News

Researchers Aim to Conquer Jet Lag Using Engineered RPE Cells
Researchers Aim to Conquer Jet Lag Using Engineered RPE Cells

Researchers at Rice and Northwestern universities have developed a subcutaneous therapy using engineered retinal pigment epithelial (RPE) cells that they say could help the body adapt more quickly ...

Ophthalmic Market Poised for Steady Growth Amid Digital Shift, Rising Demand
Ophthalmic Market Poised for Steady Growth Amid Digital Shift, Rising Demand

Ophthalmology continues to expand as global demand for eye care rises, digital technology moves deeper into clinical workflows, and manufacturers push new approaches to diagnosis and treatment. The...

AI Funding Boom Reshapes Venture Capital as Ophthalmology Investment Holds Steady
AI Funding Boom Reshapes Venture Capital as Ophthalmology Investment Holds Steady

Record venture capital investment in the first half of 2026 was driven by artificial intelligence (AI) mega-rounds, while ophthalmology continued to draw steady investor interest. AI dominated H1-2...

Tarsus Enters Retina Sector with Two Acquisitions that Could Top $1 Billion
Tarsus Enters Retina Sector with Two Acquisitions that Could Top $1 Billion

Tarsus Pharmaceuticals, maker of Xdemvy drops for Demodex blepharitis, has ventured into the retina sector recently with two acquisitions that could end up topping $1 billion. Tarsus said its deals...

Select US FDA Approvals and Clearances in July 2026
Select US FDA Approvals and Clearances in July 2026

The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in July 2026, according to the agency’s database. iHealthscreen received clearance for its iPredi...

PDUFA Dates for Ophthalmic Drug Candidates, August 2026
PDUFA Dates for Ophthalmic Drug Candidates, August 2026

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD

Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...

India’s Biocon Launches Aflibercept Biosimilar Yesafili in the US
India’s Biocon Launches Aflibercept Biosimilar Yesafili in the US

India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...

Alcon Drops Development of PowerVision Accommodating Lens
Alcon Drops Development of PowerVision Accommodating Lens

Alcon reported Aug. 10 in its Q2-2026 earnings report that it had discontinued work on the PowerVision FluidVision accommodating IOL, following analysis of the latest clinical study data. Alcon sai...

ASRS Session Builds Anticipation for GA Candidate Aiming to Preserve Vision
ASRS Session Builds Anticipation for GA Candidate Aiming to Preserve Vision

The 2026 annual meeting of the American Society of Retina Specialists offered encouraging news for patients suffering from geographic atrophy (GA). Margaret Chang, MD, MS, of the Retina Consultants...

Retinal Treatment Durability Takes Center Stage at ASRS Meeting
Retinal Treatment Durability Takes Center Stage at ASRS Meeting

Treatment durability was a recurring theme in sessions throughout the 2026 annual meeting of the American Society of Retina Specialists. Day 2 of the meeting began with a session titled, “Beyond An...

Smaller Ophthalmic Surgical Lasers Demonstrate Flexibility and Effectiveness
Smaller Ophthalmic Surgical Lasers Demonstrate Flexibility and Effectiveness

Miniaturization has emerged in recent years as a key innovation in ophthalmic surgical laser technology, and smaller laser systems were on display at the 2026 annual meeting of the American Society...

2026-2027 Ophthalmic Meetings Calendar
2026-2027 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure

Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...

Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye

Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...

Science Corp. Launches Prima Retinal Implant for GA in Europe
Science Corp. Launches Prima Retinal Implant for GA in Europe

Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...

Tarsus Leads Latest Fundraising with $125 Million Private Placement
Tarsus Leads Latest Fundraising with $125 Million Private Placement

Tarsus Pharmaceuticals led recent ophthalmic fundraising efforts with a $125 million private placement for clinical development and commercial activities. Financing announced in the past four weeks...

IPG Photonics to Acquire Lumibird Medical for $342.3 Million
IPG Photonics to Acquire Lumibird Medical for $342.3 Million

IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...

Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India
Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India

Aravind Eye Care System and Alcon reported July 24 that they had launched the Aravind Alcon Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. The move marks the s...

Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study
Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study

Glaukos reported July 27 that it had completed patient enrollment in a 510(k) pivotal study for the PreserFlo MicroShunt. The glaucoma drainage device is implanted ab externally to increase outflow...

Clinical Trial Updates for Ophthalmic Candidates, August 2026
Clinical Trial Updates for Ophthalmic Candidates, August 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444

The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...

Emerging Companies Pursuing Ophthalmic Indications
Emerging Companies Pursuing Ophthalmic Indications

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Surgeon Poll, US Ophthalmologists and Optometrists, August 2026
Weekly Surgeon Poll, US Ophthalmologists and Optometrists, August 2026

August 2026 Ophthalmic News Briefs
August 2026 Ophthalmic News Briefs

Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL delivery system in the US. The inserter is available now with the enVista Aspire intermediate-optimized mon...

US FDA Accepts NDA for Belite’s Oral Stargardt Candidate, Grants Priority Review
US FDA Accepts NDA for Belite’s Oral Stargardt Candidate, Grants Priority Review

Belite Bio announced Aug. 11 that the US FDA had accepted its new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant. The agency granted priority review, and set a Presc...

Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI
Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI

Alcon reported Aug. 10 that its Q2-2026 net sales totaled $2.8 billion, an 8 percent increase over $2.6 billion in Q2-2025. Alcon also announced that it had discontinued work on the PowerVision Flu...

Oculis Buys Out Global Rights to Privosegtor from Accure
Oculis Buys Out Global Rights to Privosegtor from Accure

Swiss company Oculis announced Aug. 10 that it would obtain worldwide development and commercialization rights to privosegtor as part of an asset purchase agreement with Spain’s Accure Therapeutics...

Italy’s Alfasigma to Acquire Nordic Pharma, Maker of Lacrifill Canalicular Gel
Italy’s Alfasigma to Acquire Nordic Pharma, Maker of Lacrifill Canalicular Gel

Italian pharmaceutical company Alfasigma announced Aug. 11 that it would acquire 100 percent of the shares of Nordic Group BV (Nordic Pharma) and its subsidiaries from Sever Life Sciences. Financia...

Nicox Partner Ocumension Submits NDA in China for Glaucoma Drop
Nicox Partner Ocumension Submits NDA in China for Glaucoma Drop

France’s Nicox announced Aug. 10 that its partner Ocumension Therapeutics, of China, had submitted a new drug application (NDA) to China’s National Medical Products Administration for NCX 470, a ni...

US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR
US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR

China’s Ractigen Therapeutics reported on July 31 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I clinical trial of ...

US FDA Grants RMAT Status to Ocugen’s Gene Therapy Candidate for GA
US FDA Grants RMAT Status to Ocugen’s Gene Therapy Candidate for GA

Ocugen announced July 29 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OCU410, the company’s subretinal gene therapy candidate for geographic atrophy (GA)...

Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million
Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million

Tarsus Pharmaceuticals, maker of Xdemvy, announced Aug. 6 that it would acquire Alkeus Pharmaceuticals in a ‌cash-and-stock deal worth up to $800 million. Under the deal, Tarsus will pay $450 milli...

Q2-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Astellas, Novartis, Lumibird, Ocular Therapeutix, and Xbrane
Q2-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Astellas, Novartis, Lumibird, Ocular Therapeutix, and Xbrane

Regeneron, of Tarrytown, New York, reported July 30 that its Q2-2026 US revenue for Eylea HD and Eylea 2 mg was $1.0 billion, a 12 percent decrease from $1.15 billion in Q2-2025. Eylea HD accounted...

Biocon Launches Eylea Biosimilar Yesafili in the US
Biocon Launches Eylea Biosimilar Yesafili in the US

India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...

Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye 

Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...

Sight Sciences Gains US FDA 510(k) Clearance for Omni Ultra Glaucoma Device
Sight Sciences Gains US FDA 510(k) Clearance for Omni Ultra Glaucoma Device

Sight Sciences announced Aug. 4 that it had gained 510(k) clearance from the US FDA for the Omni Ultra surgical system. Sight Sciences, of Menlo Park, California, said the Ultra is indicated for ca...

Topcon Gains CE Marking for Gaia Ultra-widefield Retinal Imager
Topcon Gains CE Marking for Gaia Ultra-widefield Retinal Imager

Topcon Healthcare announced July 17 that it had gained CE marking in Europe for its Gaia ultra-widefield retinal imaging device. Topcon says Gaia offers true-color fundus imaging, with a 209-degree...

Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India
Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India

Aravind Eye Care System and Alcon reported July 24 that they had launched the Aravind Alcon Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. The move marks the s...

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

STAAR Surgical, of Lake Forest, California, reported Aug. 4 that it had appointed Warren Foust as president and chief executive officer. Foust and Deborah Andrews, STAAR’s chief financial officer, ...

Roche Receives Positive CHMP Opinion for Susvimo Sustained-Release Wet AMD Treatment
Roche Receives Positive CHMP Opinion for Susvimo Sustained-Release Wet AMD Treatment

Swiss drugmaker Roche announced July 24 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for ...

Nicox Partner Kowa Submits NDA to US FDA for Glaucoma Drop
Nicox Partner Kowa Submits NDA to US FDA for Glaucoma Drop

France’s Nicox announced July 1 that its partner Kowa, of Japan, had submitted a new drug application to the US FDA for NCX 470, also known as K-911, a nitric oxide-donating bimatoprost eye drop ca...

US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD

Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...

Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study
Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study

Glaukos reported July 27 that it had completed patient enrollment in a 510(k) pivotal study for the PreserFlo MicroShunt. The glaucoma drainage device is implanted ab externally to increase outflow...

Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos

Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...

Science Corp. Launches Prima Retinal Implant in Europe
Science Corp. Launches Prima Retinal Implant in Europe

Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...

Bausch + Lomb Launches EyeGility Preloaded IOL Inserter in the US
Bausch + Lomb Launches EyeGility Preloaded IOL Inserter in the US

Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL (intraocular lens) delivery system in the US. The inserter is available now with the enVista Aspire interme...

Marketing Application Submitted in Australia for Orasis’ Presbyopia Drop
Marketing Application Submitted in Australia for Orasis’ Presbyopia Drop

Orasis Pharmaceuticals announced July 15 that its partner Aspen Australia had submitted a new drug application to Australia’s Therapeutic Goods Administration for Orasis’ pilocarpine hydrochloride ...

Santen and Kyorin to Jointly Market Eyelid Cream for Allergic Conjunctivitis in Japan
Santen and Kyorin to Jointly Market Eyelid Cream for Allergic Conjunctivitis in Japan

Japanese pharmaceutical companies Santen and Kyorin announced July 13 that they would jointly market Santen’s Alesion long-acting eyelid cream (epinastine hydrochloride 0.5%) for allergic conjuncti...

Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation
Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation

Atsena Therapeutics announced July 23 that the European Medicines Agency (EMA) had granted orphan designation to its two clinical-stage gene therapy candidates: ATSN-101 for Leber congenital amauro...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more